Table 5.
Selenium supplementation trials in humans with osteoporosis.
| Author, Year [Ref] |
Study Design | Study Population (Treated/Placebo) | Intervention Se Supplement | Intervention Duration and Follow-Up |
Primary Outcomes | Secondary Outcomes | Results | +/- |
|---|---|---|---|---|---|---|---|---|
| Walsh et al. 2021 [215] |
6-month randomized, double-blind, placebo-controlled trial | 120 Postmenopausal women ≥55 years with osteopenia or osteoporosis, UK. |
1:1:1 randomized trial; received 200 μg, 50 μg, or placebo per day of sodium selenite. | 26 weeks/ 6 month |
uNTX to Cr. | Serum Se SePP, BMD, other BTM, muscle function antioxidant, and inflammatory markers. | Urine NTx to creatinine ratio did not differ significantly between treatment groups at 26 weeks. None of the secondary or mechanistic endpoint measurements differed. |
- |
| Perri et al. 2021 [216] |
Single-center, randomized, double-blinded, placebo-controlled, multi-arm, parallel clinical trial | 490 Healthy adults, 60–74 years. PRECISE trial: (1998–2015), Denmark. |
1:1:1:1 Randomized 100, 200, 300 μg or placebo per day of selenium yeast | 6 Month/ Mean 15.9 years |
Bone turnover markers, osteocalcin, P1NP, carboxy-terminal collagen crosslinks, bone alkaline phosphatase. |
Serum Se, TFT, lipid level, antioxidant, and inflammatory markers. |
Selenium supplementation reduced P1NP at 6 months, but there were no significant effects on other BTM or after 5 years. | - |
Abbreviations: BMD: bone mineral density; DXA: dual energy X-ray absorptiometry; Se: selenium; SePP: selenoprotein P; PINP: procollagen type I N-terminal propeptide; OC: osteocalcin; uNTX to Cr: urinary resorption marker N-terminal telopeptide of type I collagen to creatine; BTM: bone turnover markers; - means no significant correlation with bone health.